Everolimus Tablets
Brand Names: Everolimus Tablets Generic
Methodology & AI Transparency ⓘ
Everolimus Tablets Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a federal NDC-monographed kinase inhibitor (51991-381, 51991-380, manufactured/labeled by Breckenridge Pharmaceutical, Inc.), Everolimus Tablets provides oral-route dosing across .75 mg/1 Tablet and .5 mg/1 Tablet under licensed medical supervision.
- 2 Real-world patient consensus: Real-world cohort score of 76% across 9 de-identified Everolimus Tablets entries.
- 3 Typical cash cost range: 30-day cash pricing ranges from $165.35 discount cash to $405.11 walk-in retail (NADAC $3.8729/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Everolimus Tablets include nausea (8.2%), headache (8%), dizziness (6.6%).
Ask our AI Specialists anything about Everolimus Tablets
Everolimus Tablets Mechanism, CYP450 Pathways & DailyMed Monograph
As a federal NDC-monographed kinase inhibitor (51991-381, 51991-380, manufactured/labeled by Breckenridge Pharmaceutical, Inc.), Everolimus Tablets provides oral-route dosing across .75 mg/1 Tablet and .5 mg/1 Tablet under licensed medical supervision.
Acting as a oral-route kinase inhibitor moiety, Everolimus Tablets (NDC 51991-381, 51991-380, manufactured/labeled by Breckenridge Pharmaceutical, Inc.) regulates downstream signaling pathways proportional to .75 mg/1 Tablet and .5 mg/1 Tablet titration and patient renal/hepatic reserve.
Clinical clearance of Everolimus Tablets (Kinase Inhibitor) relies on systemic clearance of everolimus tablets integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 8 to 12 hours per Everolimus Tablets clinical pharmacology half-life; patients absorbing at Consistent 47%–59% gastrointestinal absorption profile for Everolimus Tablets bioavailability typically observe target onset around cmax attained 2–5 hours post-administration of everolimus tablets.
FDA clinical labeling for Everolimus Tablets restricts administration in previous anaphylactoid or exfoliative reaction attributed to everolimus tablets; clinical scenarios where kinase inhibitor exposure from everolimus tablets poses unacceptable risk across .75 mg/1 Tablet, .5 mg/1 Tablet, 1 mg/1 Tablet, .25 mg/1 Tablet, with self-reported patient tracking dominated by nausea (8.2% of reports), headache (8% of reports), dizziness (6.6% of reports).
Verify medication reconciliation lists so Everolimus Tablets is not inadvertently duplicated with another kinase inhibitor.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Everolimus Tablets dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Everolimus Tablets
- Clinical scenarios where kinase inhibitor exposure from Everolimus Tablets poses unacceptable risk
Logged Side-Effect Incidence (9 Reports)
Everolimus Tablets Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Everolimus Tablets)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: There were no significant differences between groups seen in either of the coprimary endpoints; furthermore, we found no association between whole blood everolimus trough concentrations and toxicity. Seminars in oncology • 2023-01-15 • Phase III Randomized Trial | N = 39 | 88/100 | PMID 36693773 ↗ |
| Can This Approach Help? Inside the Latest Research on STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus The primary endpoint is progression-free survival (PFS), by blinded independent central review (BICR). Future oncology (London, England) • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42803451 ↗ |
| Can This Approach Help? Inside the Latest Research on Exposure-response modeling for extrapolation from adult to children patients who Only after accounting for this difference an apparent mismatch between the extrapolation from adults and the children study could be resolved. CPT: pharmacometrics & systems pharmacology • 2021-06-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33932133 ↗ |
Everolimus Tablets Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.8729/unit (~$116.19/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $405.11 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $165.35 / mo | View logs ↓ |
Everolimus Tablets Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Everolimus Tablets RxNorm Concept ID | RXN-51991381-2660 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.8729 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $405.11 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $165.35 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Everolimus Tablets Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Everolimus Tablets: FDA labeling (2026-07-01, NDC 51991-381), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Everolimus Tablets community threads and patient logs by age, biological sex, dosage, and treatment duration.